Stoke Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
I am still Charles Duncan. I'm still Biotech Analyst for Cantor. I'm excited to be here today.
And so, the next presenting panel is comprised of the two CEOs from or CEOs from Abbott Therapeutics, which is a company I don't currently cover and Stoke Therapeutics, which is a company I do cover.
So, Jeremy Levin is here from Ovid. Hi, Jeremy. Nice to see you and Stoke Therapeutics, Dr. Edward Kaye is here. And then we also are joined, and this is really a surprise great, very trivial Stokes, Chief Medical Officer's here and what are we going to talk about? So why do this panel?
Well, both of these companies have really novel approaches to treating rare diseases, particularly epilepsy but perhaps more broadly than that and really different approaches. New approaches to treating a certain diabetics are developmental and epileptic encephalopathy called Dravet syndrome. And so we're going to talk a fair amount about Dravet, but it is not just about Dravet, it's also about the company's approaches.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
